No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The Ruconest market is a subset of the larger Immune Disorders Drugs market, which focuses on treatments for conditions related to the immune system. Ruconest is a recombinant human C1 esterase inhibitor (rhC1INH) used to treat acute attacks of hereditary angioedema (HAE). HAE is a rare, genetic disorder that causes episodes of swelling in the face, extremities, gastrointestinal tract, and airway. Ruconest is administered as a subcutaneous injection and works by replacing the missing C1INH protein in the body.
Ruconest is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2014. It is currently the only FDA-approved rhC1INH for the treatment of HAE. It is also approved in the European Union, Canada, and other countries.
The Ruconest market is highly competitive, with several companies offering similar products. These include Pharming Technologies, Shire, CSL Behring, and ViroPharma. Show Less Read more
